Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects

Journal of Clinical Pharmacology

Volumn 47, Issue 7, 2007, Pages 834-840

  Lasseter, Kenneth C ^a   Gambale, Jay ^b   Pharm, D ^a,b   Jin, Bo ^b   Bergman, Art ^b   Constanzer, Marvin ^b   Dru, James ^b   Han, Tae H ^b   Majumdar, Anup ^b   Evans, Judith K ^b   Gail, Murphy ^b  

^a Clinical Pharmacology Research Unit   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Aprepitant; Bioequivalency; Fosaprepitant; Tolerability

Indexed keywords

APREPITANT; FOSAPREPITANT; POLYSORBATE 80; 2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 (3 OXO 1 PHOSPHORYL 1,2,4 TRIAZOL 5 YLMETHYL)MORPHOLINE; ANTIEMETIC AGENT; MORPHOLINE DERIVATIVE; NEUROKININ 1 RECEPTOR; PRODRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; MALE; NORMAL HUMAN; ANALYSIS OF VARIANCE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG ANTAGONISM; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ANTIEMETICS; AREA UNDER CURVE; CROSS-OVER STUDIES; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MORPHOLINES; PRODRUGS; RECEPTORS, NEUROKININ-1; THERAPEUTIC EQUIVALENCY;

EID: 34548008132     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007301800     Document Type: Article

References (13)

1. Pendergrass K, Hargreaves R, Petty KJ, Carides AD, Evans JK, Horgan KJ. Aprepitant: an oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy. Drugs Today (Bare). 2004;40:853-863. (Pubitemid 39524808)
2. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. The Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21: 4112-4119.
3. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebocontrolled trial in Latin America. Cancer. 2003;97:3090-3098.
4. de Wit R, Hesketh PJ, Warr D, et al. The oral NK1 antagonist aprepitant for prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy: a review. Am J Cancer. 2005;4:35-48. (Pubitemid 40524928)
5. Hale JJ, Mills SG, MacCoss M, et al. Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs. J Med Chem. 2000;43:1234-1241. (Pubitemid 30173749)
6. Huskey SE, Luffer-Atlas D, Dean BJ, McGowan EM, Feeney WP, Chiu SH. Substance P receptor antagonist I: conversion of phosphoramidate prodrug after i.v. administration to rats and dogs. Drug Metab Dispos. 1999;27:1367-1373.
7. Tattersall FD, Rycroft W, Cumberbatch M, et al. The novel NKl receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology. 2000; 39:652-663. (Pubitemid 30089315)
8. Van Belle S, Lichinitser MR, Navari RM, et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869: a randomized controlled trial. Cancer. 2002;94:3032-3041. (Pubitemid 34547705)
9. Cocquyt V, Van Belle S, Reinhardt RR, et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer. 2001;37:835-842. (Pubitemid 32323960)
10. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75:800-802.
11. Campos D, Pereira JR, Reinhardt RR, etal. Prevention of cisplatininduced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol. 2001;19:1759-1767. (Pubitemid 32230878)
12. Navari RM, Reinhardt RR, Gralla RJ, et al. Reduction of cisplatininduced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med. 1999;340:190-195. (Pubitemid 29063215)
13. Bergstrom M, Hargreaves RJ, Burns DH, et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatiy. 2004;55:1007-1012. (Pubitemid 38581916)